最新消息分類研發臨床進展

漢康生技 HCB301 獲選 KSMO 2026 口頭報告　HCB101 胃癌研究榮獲最佳海報發表獎 HanchorBio Announces HCB301 Oral Presentation and HCB101 Best Poster Selection at KSMO 2026

HanchorBio announced that three abstracts featuring its clinical-stage programs HCB101 and HCB301 have been accepted for presentation at KSMO 2026—the 19th Annual Meeting of the Korean Society of Medical Oncology and 2026 International Conference—held in conjunction with the 14th International Conference of the Federation of Asian Clinical Oncology (FACO), taking place September 2–4, 2026, in Seoul, Korea.

8 月 19, 2026

漢康生技推進巨噬細胞導向免疫治療策略 HCB101 全球頭頸癌研究完成首位病人給藥 HanchorBio Advances HCB101 Macrophage-Directed Immunotherapy Strategy with First Patient Dosed in Global HNSCC Study

HanchorBio announced that the first patient has been dosed in Cohort 6b of its global Phase 1b/2a HCB101-201 study

8 月 17, 2026

漢康生技取得美國 FDA Pre-IND 回覆支持下一代三特異性免疫療法 HCB303 推進開發 HanchorBio Receives FDA Pre-IND Feedback Supporting Advancement of HCB303, a Next-Generation Trispecific Immunotherapy

HanchorBio announced that it has received written responses from the U.S. Food and Drug Administration (FDA) following a Type B pre-Investigational New Drug (pre-IND) submission for HCB303, the Company’s next-generation, first-in-class trispecific immunotherapy designed to simultaneously activate innate and adaptive antitumor immunity.

8 月 12, 2026

漢康-KY子公司與臺灣癌症登月計畫俞松良教授團隊建立戰略合作　共同推進精準腫瘤醫學 HanchorBio and Taiwan Cancer Moonshot Project-NTU Subteam Led by Professor Sung-Liang Yu Establish Strategic Collaboration to Advance Precision Oncology

HanchorBio announced that its wholly owned Taiwan subsidiary has entered into a strategic collaboration with the research team led by Professor Sung-Liang Yu of National Taiwan University, a key participating team in the Taiwan Cancer Moonshot Program (TCMP). The collaboration has been formalized through a memorandum of understanding signed by HanchorBio Taiwan and Professor Yu’s team.

8 月 07, 2026

漢康-KY公布主力創新藥最新臨床進展深化巨噬細胞導向腫瘤治療策略 HanchorBio Expands Clinical Evidence Supporting Its Macrophage-Directed Oncology Strategy

HanchorBio announced updated early clinical observations from its HCB101 program.

7 月 22, 2026

漢康-KY與應世生物簽署戰略合作備忘錄，探索HCB101於難治實體瘤之聯合療法策略 HanchorBio and InxMed Sign Strategic MOU to Explore HCB101-Based Combination Therapies for Difficult-to-Treat Solid Tumors

HanchorBio announced that its subsidiary, FBD Biologics Limited, has signed a strategic memorandum of understanding (“MOU”) with InxMed (Shanghai) Co., Ltd. (“InxMed”).

7 月 08, 2026

漢康生技宣布取得 FDA Type C 會議正式紀錄，支持 HCB101 於二線胃癌／胃食管結合部癌之明確開發路徑 HanchorBio Announces FDA Type C Meeting Minutes Supporting a Clear Development Path for HCB101 in Second-Line Gastric/GEJ Cancer

HanchorBio announced receipt of the official minutes from its recent U.S. Food and Drug Administration (FDA) Type C meeting regarding the post-Phase 1 development strategy for HCB101.

6 月 30, 2026

漢康生技於 JCA-AACR 2026 發表 HCB101 胃癌及頭頸癌臨床數據，展現髓系免疫增強策略潛力 HanchorBio Showcases HCB101 Myeloid-Enhancer Strategy in Gastric Cancer and HNSCC at JCA-AACR 2026

HanchorBio, Inc. announced poster presentations of HCB101 clinical data at the 9th Japanese Cancer Association (JCA) and the American Association for Cancer Research (AACR) Special Joint Conference on Novel Therapies and Diagnostics in Upper Digestive and Head and Neck Cancers, taking place June 28-30, 2026, in Kyoto, Japan.

6 月 30, 2026

漢康生技於2026 ESMO靶向抗癌治療亞洲大會發表兩場口頭報告，展現下一代免疫療法臨床進展 HanchorBio Presents Two Oral Presentations at ESMO TAT Asia 2026 Highlighting Progress Across Its Next-Generation Immunotherapy Pipeline

HanchorBio announced that two company-sponsored clinical programs were featured in oral presentations at the European Society for Medical Oncology Targeted Anticancer Therapies Asia Congress 2026, ESMO TAT Asia 2026, held in Hong Kong.

6 月 13, 2026

漢康生技於 FOCIS 2026 發表突破性數據，支持先天免疫產品引擎布局腫瘤與自體免疫疾病 HanchorBio Presents Late-Breaking Data at FOCIS 2026 Supporting Innate-Immune Product Engine Across Oncology and Autoimmune Disease

HanchorBio announced the presentation of late-breaking clinical and translational data at the Federation of Clinical Immunology Societies Annual Meeting, FOCIS 2026, being held June 9-12, 2026, in San Francisco.

6 月 10, 2026